May 16 (Reuters) - Johnson & Johnson:
* JOHNSON & JOHNSON TO ACQUIRE PROTEOLOGIX, INC. TO LEAD IN
ATOPIC
DERMATITIS TREATMENT
* JOHNSON & JOHNSON TO ACQUIRE PROTEOLOGIX, INC. TO LEAD IN
ATOPIC
DERMATITIS TREATMENT
* J&J - PROPOSED DEAL FOR FOR $850 MILLION IN CASH
* J&J: DO NOT ANTICIPATE ANY IMPACT TO PREVIOUSLY DISCLOSED
2024
ADJUSTED EPS GUIDANCE RANGE
Source text for Eikon:
Further company coverage: